Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Liefaard · SciRah

Researcher profile · Semantic Scholar

M. Liefaard

Share profile

M. Liefaard — researcher profile on SciRah

h-index: 8
Works: 25
Citations: 461

Most-cited papers

Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping
S. Rontogianni, Eleni Synadaki, Bohui Li, M. Liefaard +4 more
2019Communications Biology203 citations Open access
Semantic Scholar
Vitamin D and C-Reactive Protein: A Mendelian Randomization Study
M. Liefaard, S. Ligthart, A. Vitezova, A. Hofman +5 more
2015PLoS ONE80 citations Open access
Semantic Scholar
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
M. Liefaard, A. van der Voort, M. van Seijen, B. Thijssen +10 more
2024npj Breast Cancer31 citations Open access
Semantic Scholar
Tumour-educated platelets for breast cancer detection: biological and technical insights
M. Liefaard, K. Moore, L. Mulder, D. van den Broek +5 more
2023British Journal of Cancer26 citations Open access
Semantic Scholar
The Way of the Future: Personalizing Treatment Plans Through Technology.
M. Liefaard, E. Lips, J. Wesseling, N. Hylton +3 more
2021American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting26 citations
Semantic Scholar
Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality
Noor A. M. Bakker, Hannah Garner, E. van Dyk, Elisa Champanhet +13 more
2025npj Breast Cancer22 citations Open access
Semantic Scholar
Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2+ breast cancer
Donna O. Debets, Kelly E. Stecker, Anastasia Piskopou, M. Liefaard +4 more
2023Cell Reports Medicine14 citations Open access
Semantic Scholar
Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival
A. van der Voort, M. Liefaard, M. V. van Ramshorst, E. V. van Werkhoven +7 more
2022Breast12 citations Open access
Semantic Scholar
Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer.
Yoni Schirris, R. Voorthuis, M. Opdam, M. Liefaard +17 more
2025The Lancet Digital Health8 citations Open access
Semantic Scholar
RNA signatures from tumor-educated platelets (TEP) enable detection of early-stage breast cancer.
M. Liefaard, E. Lips, M. Best, N. Sol +6 more
2019Annals of Oncology7 citations Open access
Semantic Scholar
Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
V. Ortíz-Maldonado, N. Martínez-Cibrian, L. Alserawan, Sergi Betriu +10 more
2024Blood6 citations
Semantic Scholar
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
M. Liefaard, A. van der Voort, M. V. van Ramshorst, J. Sanders +12 more
2023Breast Cancer Research5 citations Open access
Semantic Scholar
Predicting treatment outcome using kinome activity profiling in HER2+ breast cancer biopsies
Donna O. Debets, E. D. de Graaf, M. Liefaard, G. Sonke +3 more
2022bioRxiv5 citations Open access
Semantic Scholar
A comparative study of four cell-free DNA assays for detecting circulating tumor DNA in early breast cancer
Charlotta Mulder, E. M. Jongbloed, M. Liefaard, S. Makrodimitris +11 more
2025Breast Cancer Research4 citations Open access
Semantic Scholar
Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
M. J. Kersten, K. Saevels, E. Willems, M. Liefaard +11 more
2024Blood4 citations
Semantic Scholar
Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial
N. Tovar, V. Ortíz-Maldonado, N. Martínez-Cibrian, Sergi Betriu +7 more
2023Blood4 citations Open access
Semantic Scholar
Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial
M. J. Kersten, K. Saevels, Y. Beguin, J. Vermaat +7 more
2023Blood4 citations Open access
Semantic Scholar
Comprehensive analysis of the systemic immune landscape across breast cancer subtypes and disease stages
Noor A. M. Bakker, Hannah Garner, V. Geurts, Elisa Champanhet +11 more
2025Immuno-Oncology Technology1 citations Open access
Semantic Scholar
Rationale for and Design of Papilio-1: A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Feasibility, Safety, and Efficacy of Point-of-Care-Manufactured Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells (GLPG5301) in Relapsed/Refractory Multiple Myeloma
N. V. van de Donk, S. Anguille, Jo Caers, M. Liefaard +2 more
2023Blood1 citations Open access
Semantic Scholar
161P MammaPrint and BluePrint diagnostic tests can be robustly assessed on Whole-Transcriptome NGS platform
M. Liefaard, R. Bhaskaran, Y. Bijl, D. Israeli +16 more
2022Annals of Oncology1 citations Open access
Semantic Scholar
ECTIL: Label-efficient Computational Tumour Infiltrating Lymphocyte (TIL) assessment in breast cancer: Multicentre validation in 2,340 patients with breast cancer
Yoni Schirris, R. Voorthuis, M. Opdam, M. Liefaard +17 more
2025arXiv.org0 citations
Semantic Scholar
Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights
M. Liefaard, K. Moore, L. Mulder, D. van den Broek +5 more
2023British Journal of Cancer0 citations Open access
Semantic Scholar
145P Prognostic value of tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade: A TRAIN-2 sub study
M. Liefaard, A. van der Voort, M. van Seijen, J. Sanders +7 more
2022Annals of Oncology0 citations Open access
Semantic Scholar
Abstract PD15-07: Effect of pertuzumab plus neoadjuvant trastuzumab-based chemotherapy in early-stage HER2-positive breast cancer according to BluePrint molecularly defined breast cancer subtypes
M. Liefaard, A. van der Voort, J. Sanders, S. Vonk +9 more
2022Cancer Research0 citations
Semantic Scholar
Abstract PS10-07: Pathologic complete response and 3-year survival with or without pertuzumab using real-world data of stage II and III HER2-positive breast cancer
A. van der Voort, M. Liefaard, M. V. van Ramshorst, E. V. van Werkhoven +5 more
2021Poster Session Abstracts0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Sonke×13
Invite
G. Sonke — researcher profile on SciRah
J. Wesseling×9
Invite
J. Wesseling — researcher profile on SciRah
A. van der Voort×7
Invite
A. van der Voort — researcher profile on SciRah
E. Lips×6
Invite
E. Lips — researcher profile on SciRah

×6

Invite

L. de Munck — researcher profile on SciRah

Invite

S. Vonk — researcher profile on SciRah

Invite

H. Horlings — researcher profile on SciRah

Invite

E. Lips — researcher profile on SciRah

A. V. van Muyden×5

Invite

A. V. van Muyden — researcher profile on SciRah

L. Mittempergher×4

Invite

L. Mittempergher — researcher profile on SciRah

R. Voorthuis×4

Invite

R. Voorthuis — researcher profile on SciRah

Invite

J. Sanders — researcher profile on SciRah